Serotonin syndrome (SS) is a rare and potentially lifethreatening toxic state caused by an adverse drug reaction that leads to excessive central and peripheral serotonergic activity. This excessive serotonin hyperstimulation may be secondary to 1 standard therapeutic dose of a single agent, inadvertent interactions between various drugs, intentionally or unintentionally excessive use of particular drugs, deliberate self-harm, or recreational use of certain drugs. This review article serves as an overview of the epidemiology, pathophysiology, clinical features, diagnosis, differential diagnosis, management, and prevention of SS.
Methods
The authors conducted a MEDLINE search for the period covering 1955 to 2011.
Results
SS commonly occurs after the use of serotonergic agents alone or in combination with monoamine oxidase inhibitors. SS classically consists of a triad of signs and symptoms broadly characterized as alteration of mental status, abnormalities of neuromuscular tone, and autonomic hyperactivity. However, all 3 triads of SS may not occur simultaneously. Clinical manifestations are diverse and nonspecific, which may lead to misdiagnosis. SS can range in severity from mild to life-threatening. Most cases of SS are mild and resolve with prompt recognition and supportive care. Management of SS involves withdrawal of the offending agent(s), aggressive supportive care to treat hyperthermia and autonomic dysfunction, and occasionally the administration of serotonin antagonists— cyproheptadine or chlorpromazine. Patients with moderate and severe cases of SS require inpatient hospitalization.
Conclusions
Psychiatrists, clinicians, and general practitioners must develop increased awareness of SS due to the current increase in the use of serotonergic agents in clinical practice. As SS is a manifestation of adverse pharmacology, it is not considered an idiosyncratic drug reaction, making it predictable and highly preventable. Most cases of SS are mild and easily managed. With prompt recognition and supportive care, more severe cases of SS have a favorable prognosis.
SternbachH.The serotonin syndrome. Am J Psychiatry. 1991;148:705–713.
2.
BuckML.Serotonin syndrome: pediatric and neonatal considerations. Pediatric Pharmacotherapy. 2006:12:1–5.
3.
BoyerEW, ShannonM.The serotonin syndrome. N Engl J Med. 2005;352:1112–1120.
4.
JonesD, StoryDA.Serotonin syndrome and the anaesthetist. Anaesth Intensive Care. 2005;33:181–187.
5.
HuangV, GortneyJS.Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy. 2006;26:1784–1793.
6.
KeeganMT, BrownDR, RabinsteinAA.Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs. Anesth Analg. 2006;103:1466–1468.
7.
D'EspositoM.Serotonin neurotoxicity: implications for cognitive neuroscience and neurology. Neurology. 1998;51:1529–1530.
8.
ParkerV, WongAH, BoonHS, . Adverse reactions to St John's Wort. Can J Psychiatry. 2001;46:77–79.
9.
StrouseTB, KerrihardTN, ForscherCA, . Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. J Clin Psychopharmacol. 2006;26:681–683.
10.
IsbisterGK, HackettLP, DawsonAH, . Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol. 2003;56:441–450.
11.
SovnerR, WolfeJ.Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid. N Engl J Med. 1988;319:1671.
12.
BhataraVS, BandettiniFC.Possible interaction between sertraline and tranylcypromine. Clin Pharm. 1993;12:222–225.
13.
MarleyE, WozniakKM.Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res. 1984;18:191–203.
14.
HallM, BuckleyN.Serotonin syndrome. Australian Prescriber. 2003;26:62–63.
15.
KeckPEJr, ArnoldLM.Serotonin syndrome. Psychiatr Ann. 2000;30:333–343.
16.
WooltortonE.Triptan migraine treatments and antidepressants: risk of serotonin syndrome. CMAJ. 2006;175:874.
17.
WestphalRJ.Serotonin syndrome. J Am Psychiatr Nurses Assoc. 1999;5:97–102.
18.
GillM, LoVecchioF, SeldenB.Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med. 1999;33:457–459.
19.
DemirkiranM, JankovicJ, DeanJM.Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19:157–164.
20.
Milnacipran (savella) for fibromyalgia. Med Lett Drugs Ther. 2009;51:45–46.
21.
RajapakseS, AbeynaikeL, WickramarathneT.Venlafaxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic Parkinson disease. J Clin Psychopharmacol. 2010;30:620–622.
22.
ThomasJM, RubinEH.Case report of a toxic reaction from a combination of tryptophan and phenelzine. Am J Psychiatry. 1984;141:281–283.
23.
GuzéBH, BaxterLRJr. The serotonin syndrome: case responsive to propranolol. J Clin Psychopharmacol. 1986;6:119–120.
24.
SmilksteinMJ, SmolinskeSC, RumackBH.A case of MAO inhibitor/MDMA interaction: agony after ecstasy. J Toxicol Clin Toxicol. 1987;25:149–159.
25.
PearsonHJ.Interaction of fluoxetine with carbamazepine. J Clin Psychiatry. 1990;51:126.
26.
IruelaLM, MinguezL, MerinoJ, . Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry. 1993;150:522.
27.
GoldbergRJ, HukM.Serotonin syndrome from trazodone and buspirone. Psychosomatics. 1992;33:235–236.
28.
NeuvonenPJ, Pohjola-SintonenS, TackeU, . Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993;342:1419.
29.
InselTR, RoyBF, CohenRM, . Possible development of the serotonin syndrome in man. Am J Psychiatry. 1982;139:954–955.
NisijimaK, YoshinoT, YuiK, . Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001;890:23–31.
WalshJ.Serotonin syndrome. Anaesthesia Tutorial of the Week. 2010;1–5.
53.
DvirY, SmallwoodP.Serotonin syndrome: a complex but easily avoidable condition. Gen Hosp Psychiatry. 2008;30:284–287.
54.
ThanacoodyRHK.Serotonin syndrome. Adverse Drug React Bull. 2007;243:931–934.
55.
GelenerP, GorguluU, KutluG, . Serotonin syndrome due to duloxetine. Clin Neuropharmacol. 2011;34:127–128.
56.
IsbisterGK, BuckleyNA.The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28:205–214.
57.
RadomskiJW, DursunSM, ReveleyMA, . An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;55:218–224.
58.
MartinTG.Serotonin syndrome. Ann Emerg Med. 1996;28:520–526.
59.
KanedaY, IshimotoY, OhmoriT.Mild serotonin syndrome on fluvoxamine. Int J Neurosci. 2001;109:165–172.
60.
LantzMS.Serotonin syndrome. A common but often unrecognized psychiatric condition. Geriatrics. 2001;56:52–53.
61.
GarsideS, RosebushPI.Serotonin syndrome: not a benign toxidrome. CMAJ. 2003;169:543.
HegerlU, BottlenderR, GallinatJ, . The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci. 1998;248:96–103.
64.
IsbisterGK, BuckleyNA, WhyteIM.Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187:361–365.
65.
JacobsBL.An animal behavior model for studying central serotonergic synapses. Life Sci. 1976;19:777–785.
66.
DunkleyEJ, IsbisterGK, SibbrittD, . The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–642.
67.
AblesAZ, Nagubilli PreventionR., recognition, and management of serotonin syndrome. Am Fam Physician. 2010;81:1139–1142.
